Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Kailera Therapeutics, Inc.KLRA · Entity 4435 | Chief People Officer | April 16, 2026 | April 20, 2026 |
| Seres Therapeutics, Inc.MCRB · Entity 7191 | See Remarks | October 27, 2023 | November 01, 2023 |
| Translate Bio, Inc.TBIO · Entity 135439 | Chief Human Resources Officer | March 08, 2019 | March 12, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Kailera Therapeutics, Inc.
Report date April 16, 2026 · Filed April 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.00 · Expires 2036-04-16 | Direct | 60,000 |
Reported balance
After 2026-04-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-04-16 · Grant · Acquired 60,000 · Balance 60,000 F1: The options vest and become exercisable as to 25% of the underlying shares on April 16, 2027 and thereafter in 36 substantially equal monthly installments, subject to the Reporting Person's continued service through each such vesting date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.00 · Expires 2036-04-16 | Direct | 60,000 |
Reported balance
After 2026-04-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-04-16 · Grant · Acquired 60,000 · Balance 60,000 F2: The options vest and become exercisable, if at all, as to all of the underlying shares if (i) the average daily closing price of the Company's common stock on Nasdaq during any 30 consecutive calendar-day period during the period beginning October 16, 2026 and ending on April 16, 2030 (the "Performance Measurement Period"), or (ii) the stock price in a change in control transaction that occurs during the Performance Measurement Period, equals or exceeds $40 per share, in each case subject to the Reporting Person's continued service through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The options vest and become exercisable as to 25% of the underlying shares on April 16, 2027 and thereafter in 36 substantially equal monthly installments, subject to the Reporting Person's continued service through each such vesting date.
F2: The options vest and become exercisable, if at all, as to all of the underlying shares if (i) the average daily closing price of the Company's common stock on Nasdaq during any 30 consecutive calendar-day period during the period beginning October 16, 2026 and ending on April 16, 2030 (the "Performance Measurement Period"), or (ii) the stock price in a change in control transaction that occurs during the Performance Measurement Period, equals or exceeds $40 per share, in each case subject to the Reporting Person's continued service through such vesting date.
Seres Therapeutics, Inc.
Report date October 27, 2023 · Filed November 01, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 48,588 |
Reported balance
After 2023-10-27 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-10-27 · Exercise / conversion · Acquired 9,418 · Balance 48,588 F1: On February 3, 2023, the reporting person was granted an award of 18,835 restricted stock units ("RSUs"), which vest in the form of shares of the Issuer's common stock in two substantially equal installments upon the satisfaction of certain performance criteria. On April 27, 2023 (the "Initial Milestone Date"), the Issuer's Administrator determined that the performance criteria for the first installment were met, resulting in the vesting and settlement of the award as to 9,418 RSUs on October 27, 2023, the date that was six months from the Initial Milestone Date. The remaining 9,417 RSUs shall vest on October 27, 2024, the date that is eighteen months from the Initial Milestone Date. F2: Includes 7,424 shares of common stock acquired under the Issuer's employee stock purchase plan. |
| Common StockSEC Table I · non-derivative | Direct | 45,684 |
Reported balance
After 2023-10-30 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2023-10-30 · Sale · Disposed 2,904 · Balance 45,684 F3: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 17, 2023, solely with the intent to cover taxes in connection with the vesting of the RSUs. F4: The price reported in column 4 is a weighted average of the price. These shares were sold in multiple transactions at prices ranging from $1.35 to $1.3614, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 18,835 |
Reported balance
After 2023-04-27 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-04-27 · Grant · Acquired 18,835 · Balance 18,835 F5: Each RSU represents a contingent right to receive one share of Issuer common stock. The RSUs do not have an expiration date. F1: On February 3, 2023, the reporting person was granted an award of 18,835 restricted stock units ("RSUs"), which vest in the form of shares of the Issuer's common stock in two substantially equal installments upon the satisfaction of certain performance criteria. On April 27, 2023 (the "Initial Milestone Date"), the Issuer's Administrator determined that the performance criteria for the first installment were met, resulting in the vesting and settlement of the award as to 9,418 RSUs on October 27, 2023, the date that was six months from the Initial Milestone Date. The remaining 9,417 RSUs shall vest on October 27, 2024, the date that is eighteen months from the Initial Milestone Date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 9,417 |
Reported balance
After 2023-10-27 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-10-27 · Exercise / conversion · Disposed 9,418 · Balance 9,417 F5: Each RSU represents a contingent right to receive one share of Issuer common stock. The RSUs do not have an expiration date. F1: On February 3, 2023, the reporting person was granted an award of 18,835 restricted stock units ("RSUs"), which vest in the form of shares of the Issuer's common stock in two substantially equal installments upon the satisfaction of certain performance criteria. On April 27, 2023 (the "Initial Milestone Date"), the Issuer's Administrator determined that the performance criteria for the first installment were met, resulting in the vesting and settlement of the award as to 9,418 RSUs on October 27, 2023, the date that was six months from the Initial Milestone Date. The remaining 9,417 RSUs shall vest on October 27, 2024, the date that is eighteen months from the Initial Milestone Date. |
Filing footnotes · ownership attribution and instrument terms
F1: On February 3, 2023, the reporting person was granted an award of 18,835 restricted stock units ("RSUs"), which vest in the form of shares of the Issuer's common stock in two substantially equal installments upon the satisfaction of certain performance criteria. On April 27, 2023 (the "Initial Milestone Date"), the Issuer's Administrator determined that the performance criteria for the first installment were met, resulting in the vesting and settlement of the award as to 9,418 RSUs on October 27, 2023, the date that was six months from the Initial Milestone Date. The remaining 9,417 RSUs shall vest on October 27, 2024, the date that is eighteen months from the Initial Milestone Date.
F2: Includes 7,424 shares of common stock acquired under the Issuer's employee stock purchase plan.
F3: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 17, 2023, solely with the intent to cover taxes in connection with the vesting of the RSUs.
F4: The price reported in column 4 is a weighted average of the price. These shares were sold in multiple transactions at prices ranging from $1.35 to $1.3614, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5: Each RSU represents a contingent right to receive one share of Issuer common stock. The RSUs do not have an expiration date.
Translate Bio, Inc.
Report date March 08, 2019 · Filed March 12, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right ot buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.95 · Expires 2029-03-07 | Direct | 60,000 |
Reported balance
After 2019-03-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-03-08 · Grant · Acquired 60,000 · Balance 60,000 F1: This option will vest as to 25% of the shares on March 8, 2020, and in thirty-six equal monthly installments thereafter as to the remaining shares through March 8, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: This option will vest as to 25% of the shares on March 8, 2020, and in thirty-six equal monthly installments thereafter as to the remaining shares through March 8, 2023.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 16, 2026 Filed Apr 20, 2026 21:19 UTC | Kailera Therapeutics, Inc. KLRA · Entity 4435 | GrantStock Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001193125-26-164307 · ownership.xml · derivative · entry 2 Cloghessy Paula · CIK 0001744682 · Chief People Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2036-04-16 F2 · derivative.exercise_date: The options vest and become exercisable, if at all, as to all of the underlying shares if (i) the average daily closing price of the Company's common stock on Nasdaq during any 30 consecutive calendar-day period during the period beginning October 16, 2026 and ending on April 16, 2030 (the "Performance Measurement Period"), or (ii) the stock price in a change in control transaction that occurs during the Performance Measurement Period, equals or exceeds $40 per share, in each case subject to the Reporting Person's continued service through such vesting date. Read SEC document |
| April 16, 2026 Filed Apr 20, 2026 21:19 UTC | Kailera Therapeutics, Inc. KLRA · Entity 4435 | GrantStock Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001193125-26-164307 · ownership.xml · derivative · entry 1 Cloghessy Paula · CIK 0001744682 · Chief People Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2036-04-16 F1 · derivative.exercise_date: The options vest and become exercisable as to 25% of the underlying shares on April 16, 2027 and thereafter in 36 substantially equal monthly installments, subject to the Reporting Person's continued service through each such vesting date. Read SEC document |
| October 30, 2023 Filed Nov 1, 2023 01:43 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | SaleCommon Stock | 2,904 | $1.35 | $3,920.40 |
DisclosureSEC source: 0000899243-23-020082 · doc4.xml · nonDerivative · entry 2 Cloghessy Paula · CIK 0001744682 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 45,684 F3 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 17, 2023, solely with the intent to cover taxes in connection with the vesting of the RSUs. F4 · price: The price reported in column 4 is a weighted average of the price. These shares were sold in multiple transactions at prices ranging from $1.35 to $1.3614, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 27, 2023 Filed Nov 1, 2023 01:43 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionRestricted Stock Units · Derivative | 9,418 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-020082 · doc4.xml · derivative · entry 4 Cloghessy Paula · CIK 0001744682 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,417 Underlying: Common Stock · 9,418 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. The RSUs do not have an expiration date. F1 · shares: On February 3, 2023, the reporting person was granted an award of 18,835 restricted stock units ("RSUs"), which vest in the form of shares of the Issuer's common stock in two substantially equal installments upon the satisfaction of certain performance criteria. On April 27, 2023 (the "Initial Milestone Date"), the Issuer's Administrator determined that the performance criteria for the first installment were met, resulting in the vesting and settlement of the award as to 9,418 RSUs on October 27, 2023, the date that was six months from the Initial Milestone Date. The remaining 9,417 RSUs shall vest on October 27, 2024, the date that is eighteen months from the Initial Milestone Date. F1 · derivative.exercise_date: On February 3, 2023, the reporting person was granted an award of 18,835 restricted stock units ("RSUs"), which vest in the form of shares of the Issuer's common stock in two substantially equal installments upon the satisfaction of certain performance criteria. On April 27, 2023 (the "Initial Milestone Date"), the Issuer's Administrator determined that the performance criteria for the first installment were met, resulting in the vesting and settlement of the award as to 9,418 RSUs on October 27, 2023, the date that was six months from the Initial Milestone Date. The remaining 9,417 RSUs shall vest on October 27, 2024, the date that is eighteen months from the Initial Milestone Date. F5 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. The RSUs do not have an expiration date. Read SEC document |
| October 27, 2023 Filed Nov 1, 2023 01:43 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionCommon Stock | 9,418 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-020082 · doc4.xml · nonDerivative · entry 1 Cloghessy Paula · CIK 0001744682 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 48,588 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: On February 3, 2023, the reporting person was granted an award of 18,835 restricted stock units ("RSUs"), which vest in the form of shares of the Issuer's common stock in two substantially equal installments upon the satisfaction of certain performance criteria. On April 27, 2023 (the "Initial Milestone Date"), the Issuer's Administrator determined that the performance criteria for the first installment were met, resulting in the vesting and settlement of the award as to 9,418 RSUs on October 27, 2023, the date that was six months from the Initial Milestone Date. The remaining 9,417 RSUs shall vest on October 27, 2024, the date that is eighteen months from the Initial Milestone Date. F2 · balance_after: Includes 7,424 shares of common stock acquired under the Issuer's employee stock purchase plan. Read SEC document |
| April 27, 2023 Filed Nov 1, 2023 01:43 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | GrantRestricted Stock Units · Derivative | 18,835 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-020082 · doc4.xml · derivative · entry 3 Cloghessy Paula · CIK 0001744682 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,835 Underlying: Common Stock · 18,835 shares Expires not disclosed F5 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. The RSUs do not have an expiration date. F1 · shares: On February 3, 2023, the reporting person was granted an award of 18,835 restricted stock units ("RSUs"), which vest in the form of shares of the Issuer's common stock in two substantially equal installments upon the satisfaction of certain performance criteria. On April 27, 2023 (the "Initial Milestone Date"), the Issuer's Administrator determined that the performance criteria for the first installment were met, resulting in the vesting and settlement of the award as to 9,418 RSUs on October 27, 2023, the date that was six months from the Initial Milestone Date. The remaining 9,417 RSUs shall vest on October 27, 2024, the date that is eighteen months from the Initial Milestone Date. F1 · derivative.exercise_date: On February 3, 2023, the reporting person was granted an award of 18,835 restricted stock units ("RSUs"), which vest in the form of shares of the Issuer's common stock in two substantially equal installments upon the satisfaction of certain performance criteria. On April 27, 2023 (the "Initial Milestone Date"), the Issuer's Administrator determined that the performance criteria for the first installment were met, resulting in the vesting and settlement of the award as to 9,418 RSUs on October 27, 2023, the date that was six months from the Initial Milestone Date. The remaining 9,417 RSUs shall vest on October 27, 2024, the date that is eighteen months from the Initial Milestone Date. F5 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. The RSUs do not have an expiration date. Read SEC document |
| February 03, 2023 Filed Feb 7, 2023 22:42 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | GrantStock Option (Right to Buy) · Derivative | 95,000 | $0.00 Strike: $5.50 | $0.00 |
DisclosureSEC source: 0000899243-23-004197 · doc4.xml · derivative · entry 2 Cloghessy Paula · CIK 0001744682 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,000 Underlying: Common Stock · 95,000 shares Expires 2033-02-02 F3 · derivative.exercise_date: The option will vest as to 25% of the shares on February 3, 2024. The remainder of the shares will vest in 12 equal quarterly installments thereafter. Read SEC document |
| February 03, 2023 Filed Feb 7, 2023 22:42 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | GrantRestricted Stock Units · Derivative | 47,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-004197 · doc4.xml · derivative · entry 1 Cloghessy Paula · CIK 0001744682 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,500 Underlying: Common Stock · 47,500 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F2 · derivative.exercise_date: The restricted stock units will vest and settle as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units will vest and settle in 12 equal quarterly installments thereafter. F2 · derivative.expiration_date: The restricted stock units will vest and settle as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units will vest and settle in 12 equal quarterly installments thereafter. Read SEC document |
| July 05, 2022 Filed Jul 6, 2022 23:25 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | GrantCOMMON STOCK | 31,746 | $3.15 | $99,999.90 |
DisclosureSEC source: 0000899243-22-025518 · doc4.xml · nonDerivative · entry 1 Cloghessy Paula · CIK 0001744682 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,746 Read SEC document |
| February 07, 2022 Filed Feb 9, 2022 02:35 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | GrantStock Options (right to buy) · Derivative | 190,000 | $0.00 Strike: $7.60 | $0.00 |
DisclosureSEC source: 0000899243-22-005322 · doc4.xml · derivative · entry 1 Cloghessy Paula · CIK 0001744682 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 190,000 Underlying: Common Stock · 190,000 shares Expires 2032-02-06 F1 · derivative.exercise_date: This option will vest and become exercisable as to 25% of the shares on February 7, 2023. The remainder of the shares will vest and become exercisable in 12 equal quarterly installments thereafter. Read SEC document |
| March 08, 2019 Filed Mar 12, 2019 18:11 UTC | Translate Bio, Inc. TBIO · Entity 135439 | GrantStock Option (right ot buy) · Derivative | 60,000 | $0.00 Strike: $7.95 | $0.00 |
DisclosureSEC source: 0001209191-19-018953 · doc4.xml · derivative · entry 1 Cloghessy Paula · CIK 0001744682 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2029-03-07 F1 · derivative.exercise_date: This option will vest as to 25% of the shares on March 8, 2020, and in thirty-six equal monthly installments thereafter as to the remaining shares through March 8, 2023. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.